A Review of Management of Clostridium difficile Infection: Primary and Recurrence
Abstract
:1. Introduction
2. Recurrent Clostridium difficile Infection
Risk Factors for Recurrent CDI
3. Treatment Options for CDI
3.1. Antibiotics
3.1.1. Metronidazole
3.1.2. Glycopeptides
Vancomycin
Teicoplanin
3.1.3. Rifamycins
3.1.4. Fidaxomicin
3.2. Immune Therapy
3.2.1. Active Immunization
3.2.2. Passive Immunization
3.3. Microbial Therapy
3.3.1. Probiotics
3.3.2. Bacteriotherapy
Fecal Microbiota Transplantation
3.3.3. Non Toxigenic Clostridium difficile Spores
4. FMT Clinical Trials
5. Conclusions
Author Contributions
Conflicts of Interest
References
- McDonald, L.C.; Owings, M.; Jernigan, D.B. Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996–2003. Emerg. Infect. Dis. 2006, 12, 409–415. [Google Scholar] [CrossRef] [PubMed]
- Lessa, C.F.; Mu, Y.; Bamberg, M.W.; Beldavs, G.Z.; Dumyati, K.G.; Dunn, R.J.; Farley, M.M.; Holzbauer, M.S.; Meek, I.J.; Phipps, C.E.; et al. Burden of Clostridium difficile infection in the United States. N. Engl. J. Med. 2015, 372, 825–834. [Google Scholar] [CrossRef] [PubMed]
- Lucado, J.; Could, C.; ELixhauser, A. Clostridium difficile infections (CDI) in Hospital Stays, 2009. HCUP Statistical Brief #124. January 2012. Agency for Healthcare Research and Quality: Rockville, MD, USA.
- Loo, V.G.; Poirier, L.; Miller, M.A.; Oughton, M.; Libman, M.D.; Michaud, S.; Bourgault, A.; Nguyen, T.; Frenette, C.; Kelly, M. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N. Engl. J. Med. 2005, 353, 2442–2449. [Google Scholar] [CrossRef] [PubMed]
- Gravel, D.; Miller, M.; Simor, A.; Taylor, G.; Gardam, M.; McGeer, A.; Hutchinson, J.; Moore, D.; Kelly, S.; Boyd, D.; et al. Canadian Nosocomial Infection Surveillance Program Health care-associated Clostridium difficile infection in adults admitted to acute care hospitals in Canada: A Canadian Nosocomial Infection Surveillance Program Study. Clin. Infect. Dis. 2009, 48, 568–576. [Google Scholar] [CrossRef] [PubMed]
- McDonald, L.C. the Changing Epidemiology of Clostridium difficile; Clostridium difficile: Changing Diagnosis, Epidemiology and Treatment, Proceedings of the Satellite Symposium during the 18th Annual SHEA Scientific Meeting; Orlando, FL, USA, 2008.
- Gabriel, L.; Beriot-Mathiot, A. Hospitalization stay and costs attributable to Clostridium difficile infection: A critical review. J. Hosp. Infect. 2014, 88, 12–21. [Google Scholar] [CrossRef] [PubMed]
- Ghantoji, S.S.; Sail, K.; Larison, D.R.; DuPont, H.L.; Garey, K.W. Economic healthcare costs of Clostridium difficile infect: A systematic review. J. Hosp. Infect. 2010, 74, 309–318. [Google Scholar] [CrossRef] [PubMed]
- Johnson, S.; Adelmann, A.; Clabots, C.R.; Peterson, L.; Gerding, D. Recurrences of Clostridium difficile diarrhea not caused by the original infecting organism. J. Infect. Dis. 1989, 159, 340–343. [Google Scholar] [CrossRef] [PubMed]
- O’Neill, G.L.; Beaman, M.H.; Riley, T.V. Relapse vs. reinfection with Clostridium difficile. Epidemiol. Infect. 1991, 107, 627–635. [Google Scholar] [CrossRef] [PubMed]
- McFarland, L.V.; Elmer, G.W.; Surawicz, C.M. Breaking the cycle: Treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am. J. Gastroenterol. 2002, 97, 1769–1775. [Google Scholar] [CrossRef] [PubMed]
- Bakken, J.S. Fecal bacteriotherapy for recurrent Clostridium difficile infection. Anaerobe 2009, 15, 285–289. [Google Scholar] [CrossRef] [PubMed]
- Hopkins, M.J.; Macfarlane, G.T. Changes in predominant bacterial populations in human faeces with age and with Clostridium difficile infection. J. Med. Microbiol. 2002, 51, 448–454. [Google Scholar] [CrossRef] [PubMed]
- Poutanen, M.S.; Simor, A.E. Clostridium difficile-associated diarrhea in adults. Can. Med. Assoc. J. 2004, 171, 51–58. [Google Scholar] [CrossRef]
- Drekonja, D.M.; Amundson, W.H.; DeCarolis, D.D.; Kuskowski, M.A.; Lederle, F.A.; Johnson, J.R. Antimicrobial use and risk for recurrent Clostridium difficile infection. Am. J. Med. 2011, 124, 1081.e1–1081.e7. [Google Scholar] [CrossRef] [PubMed]
- Pepin, J.; Alary, M.E.; Valiquette, L.; Raiche, E.; Ruel, J.; Fulop, K.; Godin, D.; Bourassa, C. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin. Infect. Dis. 2005, 40, 1591–1597. [Google Scholar] [CrossRef] [PubMed]
- Hu, M.Y.; Katchar, K.; Kyne, L.; Maroo, S.; Tummala, S.; Dreisbach, V.; Xu, H.; Leffler, D.A.; Kelly, C.P. Prospective derivation and validation of a clinical prediction rule for recurrent Clostridium difficile infection. Gastroenterology 2009, 136, 1206–1214. [Google Scholar] [CrossRef] [PubMed]
- McFarland, L.V.; Surawicz, C.M.; Greenberg, R.N.; Fekety, R.; Elmer, G.W.; Moyer, K.A.; Melcher, S.A.; Bowen, K.E.; Cox, J.L.; Noorani, Z. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA 1994, 271, 1913–1918. [Google Scholar] [CrossRef] [PubMed]
- Leung, D.Y.; Kelly, C.P.; Boguniewicz, M.; Pothoulakis, C.; LaMont, J.T.; Flores, A. Treatment with intravenously administered gamma globulin of chronic relapsing colitis induced by Clostridium difficile toxin. J. Pediatr. 1991, 118, 633–637. [Google Scholar] [CrossRef]
- Pepin, J.; Routhier, S.; Gagnon, S.; Brazeau, I. Management and outcomes of a first recurrence of Clostridium difficile-associated disease in Quebec, Canada. Clin. Infect. Dis. 2006, 42, 758–764. [Google Scholar] [CrossRef] [PubMed]
- Zilberberg, M.D.; Reske, K.; Olsen, M.; Yan, Y.; Debberke, E.R. Risk factors for recurrent Clostridium difficile infection (CDI) hospitalization among hospitalized patients with an initial episode: A retrospective cohort study. BMC Infect. Dis. 2014, 14. [Google Scholar] [CrossRef] [PubMed]
- Cocanour, C.S. Best strategies in recurrent or persistent Clostridium difficile infection. Surg. Infect. 2011, 12, 235–239. [Google Scholar] [CrossRef] [PubMed]
- Cohen, S.H.; Gerding, D.N.; Johnson, S.; Kelly, C.P.; Loo, V.G.; McDonald, L.C.; Pepin, J.; Wilcox, M.H. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 Update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect. Control 2010, 31, 431–455. [Google Scholar]
- Musher, D.M.; Aslam, S.; Logan, N.; Nallacheru, S.; Bhaila, I.; Borchert, F.; Hamill, R.J. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin. Infect. Dis. 2005, 40, 1586–1590. [Google Scholar] [CrossRef] [PubMed]
- Johnson, S.; Louie, T.J.; Gerding, D.N.; Cornely, O.A.; Chasan-Taber, S.; Fitts, D.; Gelone, S.P.; Broom, C.; Davidson, D.M. Polymer Alternative for CDI Treatment (PACT) investigators Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: Results from two multinational, randomized, controlled trials. Clin. Infect. Dis. 2014, 59, 345–354. [Google Scholar] [CrossRef] [PubMed]
- Teasley, D.; Olson, M.; Gebhard, R.; Gerding, D.; Peterson, L.; Schwartz, M.; Lee, J. Prospective randomised trial of metronidazole vs. vancomycin for Clostridium-difficile-associated diarrhoea and colitis. Lancet 1983, 322, 1043–1046. [Google Scholar] [CrossRef]
- Vardakas, K.Z.; Polyzos, K.A.; Patouni, K.; Rafailidis, P.I.; Samonis, G.; Falagas, M.E. Treatment failure and recurrence of Clostridium difficile infection following treatment with vancomycin or metronidazole: A systematic review of the evidence. Int. J. Antimicrob. Agnets 2012, 40, 1–8. [Google Scholar] [CrossRef] [PubMed]
- Wenisch, C.; Parschalk, B.; Hasenhundl, M.; Hirschl, A.M.; Graninger, W. Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea. Clin. Infect. Dis. 1996, 22, 813–818. [Google Scholar] [CrossRef] [PubMed]
- Zar, F.A.; Bakkanagari, S.R.; Moorthi, K.M.; Davis, M.B. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin. Infect. Dis. 2007, 45, 302–307. [Google Scholar] [CrossRef] [PubMed]
- Fekety, R.; McFarland, L.V.; Surawicz, C.M.; Greenberg, R.N.; Elmer, G.W.; Mulligan, M.E. Recurrent Clostridium difficile diarrhea: Characteristics of and risk factors for patients enrolled in a prospective, randomized, double-blinded trial. Clin. Infect. Dis. 1997, 24, 324–333. [Google Scholar] [CrossRef] [PubMed]
- Gerding, D. Treatment of Clostridium difficile-associated Diarrhea and Colitis; Clostridium difficile. Curr. Top. Microbiol. Immunol. 2000, 250, 127–139. [Google Scholar] [PubMed]
- Tedesco, F.J.; Gordon, D.; Fortson, W.C. Approach to patients with multiple relapses of antibiotic-associated pseudomembranous colitis. Am. J. Gastroenterol. 1985, 80, 867–868. [Google Scholar] [PubMed]
- Garey, K.W.; Jiang, Z.D.; Bellard, A.; Dupont, H.L. Rifaximin in treatment of recurrent Clostridium difficile-associated diarrhea: An uncontrolled pilot study. J. Clin. Gastroenterol. 2009, 43, 91–93. [Google Scholar] [CrossRef] [PubMed]
- Johnson, S.; Schriever, C.; Patel, U.; Patel, T.; Hecht, D.W.; Gerding, D.N. Rifaximin redux: Treatment of recurrent Clostridium difficile infections with rifaximin immediately post-vancomycin treatment. Anaerobe 2009, 15, 290–291. [Google Scholar] [CrossRef] [PubMed]
- Johnson, S.; Schriever, C.; Galang, M.; Kelly, C.P.; Gerding, D.N. Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin. Clin. Infect. Dis. 2007, 44, 846–848. [Google Scholar] [CrossRef] [PubMed]
- Louie, T.; Miller, M.; Donskey, C.; Mullane, K.; Goldstein, E. Clinical Outcomes, Safety, and Pharmacokinetics of OPT-80 in a Phase 2 Trial with Patients with Clostridium difficile Infection. Antimicrob. Agents Chemother. 2009, 53, 223–228. [Google Scholar] [CrossRef] [PubMed]
- Miller, M. Faster time to resolution of diarrhea with fidaxomicin vs. vancomycin in patients with Clostridium difficile infection. In Proceedings of the 47th Annual Meeting; IDSA: Philadelphia, PA, USA, 2009. [Google Scholar]
- Johnson, A.P. Drug evaluation: OPT-80, a narrow-spectrum macrocyclic antibiotic. Curr. Opin. Investig. Drugs. 2007, 8, 168–173. [Google Scholar] [PubMed]
- Crook, D.W.; Walker, A.S.; Kean, Y.; Weiss, K.; Cornely, O.A.; Miller, M.A.; Esposito, R.; Louie, T.J.; Stoesser, N.E.; Young, B.C.; et al. Fidaxomicin vs. vancomycin for Clostridium difficile infection: Meta-analysis of pivotal randomized controlled trials. Clin. Infect. Dis. 2012, 55 (Suppl. S2), S93–S103. [Google Scholar]
- Miller, M. Fidaxomicin (OPT-80) for the treatment of Clostridium difficile infection. Expert Opin. Pharmacother. 2010, 11, 1569–1578. [Google Scholar] [CrossRef] [PubMed]
- Esmaily-Fard, A.; Tverdek, F.P.; Crowther, D.M.; Ghantoji, S.S.; Adachi, J.A.; Chemaly, R.F. The use of fidaxomicin for treatment of replapsed Clostridium difficile infections in patients with Cancer. Pharmacother.: J. Hum. Pharmacol. Drug Therapy 2004, 34, 1220–1225. [Google Scholar] [CrossRef] [PubMed]
- Sougioultzis, S.; Kyne, L.; Drudy, D.; Keates, S.; Maroo, S.; Pothoulakis, C.; Giannasca, P.J.; Lee, C.K.; Warny, M.; Monath, T.P. Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea. Gastroenterology 2005, 128, 764–770. [Google Scholar] [CrossRef] [PubMed]
- Lowy, I.; Molrine, D.C.; Leav, B.A.; Blair, B.M.; Baxter, R.; Gerding, D.N.; Nichol, G.; Thomas, W.D., Jr.; Leney, M.; Sloan, S. Treatment with monoclonal antibodies against Clostridium difficile toxins. N. Engl. J. Med. 2010, 362. [Google Scholar] [CrossRef] [PubMed]
- Girardin, M.; Seidman, E.G. Indications for the use of probiotics in gastrointestinal diseases. Dig. Dis. 2011, 29, 574–587. [Google Scholar] [CrossRef] [PubMed]
- Pillai, A.; Nelson, R.L. Probiotics for treatment of Clostridium difficile-associated colitis in adults. Cochrane Libr. 2008. [Google Scholar] [CrossRef]
- van Nispen tot Pannerden, C.M.; Verbon, A.; Kuipers, E.J. Recurrent Clostridium difficile infection: What are the treatment options? Drugs 2011, 71, 853–868. [Google Scholar] [CrossRef] [PubMed]
- Lherm, T.; Monet, C.; Nougière, B.; Soulier, M.; Larbi, D.; Le Gall, C.; Caen, D.; Malbrunot, C. Seven cases of fungemia with Saccharomyces boulardii in critically ill patients. Intensive Care Med. 2002, 28, 797–801. [Google Scholar] [CrossRef] [PubMed]
- Munoz, P.; Bouza, E.; Cuenca-Estrella, M.; Eiros, J.M.; Perez, M.J.; Sanchez-Somolinos, M.; Rincon, C.; Hortal, J.; Pelaez, T. Saccharomyces cerevisiae fungemia: An emerging infectious disease. Clin. Infect. Dis. 2005, 40, 1625–1634. [Google Scholar] [CrossRef] [PubMed]
- Zhang, F.; Luo, W.; Shi, Y.; Fan, Z.; Ji, G. Should we standardize the 1700-year-old fecal microbiota transplantation? Am. J. Gastroenterol. 2012, 107. [Google Scholar] [CrossRef]
- Schwan, A.; Sjolin, S.; Trottestam, U.; Aronsson, B. Relapsing Clostridium difficile enterocolitis cured by rectal infusion of normal faeces. Scand. J. Infect. Dis. 1984, 16, 211–215. [Google Scholar] [CrossRef] [PubMed]
- McFarland, L.V.; Mulligan, M.E.; Kwok, R.Y.; Stamm, W.E. Nosocomial acquisition of Clostridium difficile infection. N. Engl. J. Med. 1989, 320, 204–210. [Google Scholar] [CrossRef] [PubMed]
- Rao, S.S.; Edwards, C.A.; Austen, C.J.; Bruce, C.; Read, N.W. Impaired colonic fermentation of carbohydrate after ampicillin. Gastroenterology 1988, 94, 928–932. [Google Scholar] [PubMed]
- Aas, J.; Gessert, C.E.; Bakken, J.S. Recurrent Clostridium difficile colitis: Case series involving 18 patients treated with donor stool administered via a nasogastric tube. Clin. Infect. Dis. 2003, 36, 580–585. [Google Scholar] [CrossRef] [PubMed]
- Bakken, J.S.; Borody, T.; Brandt, L.J.; Brill, J.V.; Demarco, D.C.; Franzos, M.A.; Kelly, C.; Khoruts, A.; Louie, T.; Martinelli, L.P. Treating Clostridium difficile infection with fecal microbiota transplantation. Clin. Gastroenterol. Hepatol. 2011, 9, 1044–1049. [Google Scholar] [CrossRef] [PubMed]
- Van Nood, E.; Vrieze, A.; Nieuwdorp, M.; Fuentes, S.; Zoetendal, E.G.; de Vos, W.M.; Visser, C.E.; Kuijper, E.J.; Bartelsman, J.F.; Tijssen, J.G.; et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N. Engl. J. Med. 2013, 368, 407–415. [Google Scholar] [CrossRef] [PubMed]
- Surawicz, C.M.; Brandt, L.J.; Binion, D.G.; Ananthakrishnan, A.N.; Curry, S.R.; Gilligan, P.H.; McFarland, L.V.; Mellow, M.; Zuckerbraun, B.S. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am. J. Gastroenterol. 2013, 108, 478–498. [Google Scholar] [CrossRef] [PubMed]
- Kassam, Z.; Murray, T.S. Navigating the pediatric microbiome: Emerging evidence and clinical implications. Curr. Pediatr. Rep. 2014, 2, 93–101. [Google Scholar] [CrossRef]
- Brandt, L.J.; Aroniadis, O.C.; Mellow, M.; Kanatzar, A.; Kelly, C.; Park, T.; Stollman, N.; Rohlke, F.; Surawicz, C. Long-term follow-up of colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection. Am. J. Gastroenterol. 2012, 107, 1079–1087. [Google Scholar] [CrossRef] [PubMed]
- Garborg, K.; Waagsbø, B.; Stallemo, A.; Matre, J.; Sundøy, A. Results of faecal donor instillation therapy for recurrent Clostridium difficile-associated diarrhoea. Scand. J. Infect. Dis. 2010, 42, 857–861. [Google Scholar] [CrossRef] [PubMed]
- Brandt, L.J.; Aroniadis, O.C. An overview of fecal microbiota transplantation: Techniques, indications, and outcomes. Gastrointest. Endosc. 2013, 78, 240–249. [Google Scholar] [CrossRef] [PubMed]
- Youngster, I.; Sauk, J.; Pindar, C.; Wilson, R.G.; Kaplan, J.L.; Smith, M.B.; Alm, E.J.; Gevers, D.; Russell, G.H.; Hohmann, E.L. Fecal microbiota transplant for relapsing Clostridium difficile infection using a frozen inoculum from unrelated donors: A randomized, open-label, controlled pilot study. Clin. Infect. Dis. 2014, 58, 1515–1522. [Google Scholar] [CrossRef] [PubMed]
- Lüning, T.; Keemers-Gels, M.; Barendregt, W.; Tan, A.; Rosman, C. Colonoscopic perforations: A review of 30,366 patients. Surg. Endosc. 2007, 21, 994–997. [Google Scholar] [CrossRef] [PubMed]
- Kassam, Z.; Hundal, R.; Marshall, J.; Lee, C.H. Fecal Transplant via Retention Enema for Refractory or Recurrent Clostridium difficile Infection. Arch. Intern. Med. 2012, 172, 191–193. [Google Scholar] [CrossRef] [PubMed]
- Silverman, M.S.; Davis, I.; Pillai, D.R. Success of self-administered home fecal transplantation for chronic Clostridium difficile infection. Clin. Gastroenterol. Hepatol. 2010, 8, 471–473. [Google Scholar] [CrossRef] [PubMed]
- Zipursky, J.S.; Sidorsky, T.I.; Freedman, C.A.; Sidorsky, M.N.; Kirkland, K.B. Patient attitudes toward the use of fecal microbiota transplantation in the treatment of recurrent Clostridium difficile infection. Clin. Infect. Dis. 2012, 55, 1652–1658. [Google Scholar] [CrossRef] [PubMed]
- Wettstein, A.; Borody, T.; Leis, S.; Chongnan, J.; Torres, M.; Hills, L. Fecal bacteriotherapy—An effective treatment for relapsing symptomatic Clostridium difficile infection. Gut 2007, 56 (Suppl. III), A303. [Google Scholar]
- Guo, B.; Harstall, C.; Louie, T.; Veldhuyzen van Zanten, S.; Dieleman, L. Systematic review: Faecal transplantation for the treatment of Clostridium difficile-associated disease. Aliment. Pharmacol. Ther. 2012, 35, 865–875. [Google Scholar] [CrossRef] [PubMed]
- Jiang, Z.; Ajami, N.; Lasco, T.; Petrosino, J.; Hochman, F.; Ankoma-Sey, V.; Wong, M.; Alexander, A.; Ke, S.; DuPont, H. Fresh, Frozen, or Lyophilized Fecal Microbiota Transplantation (FMT) for Multiple Recurrent C. difficile Infection (CDI). Am. J. Gastroenterol. 2014, 109, S213. [Google Scholar]
- Gerding, D.N.; Meyer, T.; Lee, C.H.; Cohen, S.H.; Murthy, U.K.; Poirier, A.; van Schooneveld, T.C.; Pardi, D.S.; Ramos, A.; Barron, M.A. Administration of Spores of Nontoxigenic Clostridium difficile Strain M3 for Prevention of Recurrent C. difficile Infection: A Randomized Clinical Trial. J. Am. Med. Associ. 2015, 313, 1719–1727. [Google Scholar] [CrossRef] [PubMed]
- Rohlke, F.; Stollman, N. Fecal microbiota transplantation in relapsing Clostridium difficile infection. Ther. Adv. Gastroenterol. 2012, 5, 403–420. [Google Scholar] [CrossRef] [PubMed]
- FMT Delivered by Capsule versus Colonoscopy for Recurrent C. difficile. Available online: http://www.clinicaltrials.gov/ct2/show/NCT02254811?term=NCT02254811&rank=1 (accessed on 25 June 2015).
- A Prospective Trial of Frozen-and-Thawed Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection. Available online: http://www.clinicaltrials.gov/ct2/show/NCT02394275?term=NCT02394275&rank=1 (accessed on 25 June 2015).
- Fecal Microbiota Transplantation for C difficile Infection. Available online: http://www.clinicaltrials.gov/ct2/show/NCT01905709?term=NCT01905709&rank=1 (accessed on 25 June 2015).
© 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Vincent, Y.; Manji, A.; Gregory-Miller, K.; Lee, C. A Review of Management of Clostridium difficile Infection: Primary and Recurrence. Antibiotics 2015, 4, 411-423. https://doi.org/10.3390/antibiotics4040411
Vincent Y, Manji A, Gregory-Miller K, Lee C. A Review of Management of Clostridium difficile Infection: Primary and Recurrence. Antibiotics. 2015; 4(4):411-423. https://doi.org/10.3390/antibiotics4040411
Chicago/Turabian StyleVincent, Yasmeen, Arif Manji, Kathleen Gregory-Miller, and Christine Lee. 2015. "A Review of Management of Clostridium difficile Infection: Primary and Recurrence" Antibiotics 4, no. 4: 411-423. https://doi.org/10.3390/antibiotics4040411